anthracycline, cytarabine, Daiichi Sankyo, quizartinib, Vanflyta
Quizartinib is approved by the FDA for newly diagnosed acute myeloid leukemia
August 2023: The treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test, with standard cytarabine and anthracycl..
am-trastuzumab deruxtecan-nxki, Daiichi Sankyo, Enhertu
Accelerated approval is granted by FDA to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer
August 2022: For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation resulting in mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test, the Food..
Daiichi Sankyo, DESTINY-Breast04, Enhertu, fam-trastuzumab deruxtecan-nxki
Fam-trastuzumab deruxtecan-nxki is approved by FDA for HER2-low breast cancer
August 2022: For adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH) breast cancer who have received prior chemotherapy in the metastatic setting or experienced a disease recurrence during or within six..
Daiichi Sankyo, Enhertu, fam-trastuzumab deruxtecan-nxki
Fam-trastuzumab deruxtecan-nxki is approved by FDA for breast cancer
April 2022: Adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have develop..